Blue Owl Capital Holdings LP Cuts Position in Disc Medicine, Inc. $IRON

Blue Owl Capital Holdings LP decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 16.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 102,260 shares of the company’s stock after selling 20,000 shares during the period. Disc Medicine accounts for 2.1% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 17th largest position. Blue Owl Capital Holdings LP’s holdings in Disc Medicine were worth $6,757,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. TimesSquare Capital Management LLC bought a new stake in shares of Disc Medicine in the 3rd quarter worth approximately $12,038,000. Y Intercept Hong Kong Ltd increased its position in Disc Medicine by 361.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after buying an additional 33,905 shares in the last quarter. Atle Fund Management AB raised its stake in Disc Medicine by 85.3% during the third quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after buying an additional 21,038 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Disc Medicine by 11.1% during the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after buying an additional 84,278 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Disc Medicine in the third quarter worth $689,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IRON shares. Wedbush cut their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Morgan Stanley set a $75.00 price target on Disc Medicine in a research report on Tuesday, February 17th. Truist Financial dropped their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Stifel Nicolaus cut their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Finally, BMO Capital Markets reduced their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and an average price target of $104.80.

Insider Buying and Selling

In other Disc Medicine news, insider William Jacob Savage sold 7,378 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $65.88, for a total value of $486,062.64. Following the completion of the transaction, the insider owned 85,211 shares of the company’s stock, valued at approximately $5,613,700.68. The trade was a 7.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. This represents a 5.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 292,492 shares of company stock worth $25,423,925 in the last three months. 3.64% of the stock is currently owned by company insiders.

Disc Medicine Stock Performance

Shares of IRON opened at $61.18 on Friday. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -10.21 and a beta of 0.87. The business’s fifty day simple moving average is $72.69 and its two-hundred day simple moving average is $75.50. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The company has a current ratio of 21.94, a quick ratio of 23.45 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, topping the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. Research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.